[1] MO H, HUANG J, XU J, et al.Safety, anti-tumour activity, and pharmacokinetics of fixed- dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose- escalation, phase 1 study[J]. Br J Cancer, 2018, 119(5): 538-545 [2] MARKHAM A, KEAM SJ.Camrelizumab: first global approval[J]. Drugs, 2019, 79(12): 1355-1361. [3] Guidelines Working Committee of Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) immune checkpoint inhibitor-related toxicity management guidelines(中国临床肿瘤学会 (CSCO) 免疫检查点抑制剂相关的毒性管理指南)[M]. Beijing: People's Medical Publishing House, 2019. [4] FAN QQ, ZHANG B, ZHAO B, et al.Nephrotoxicity of immune checkpoint inhibitors[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(10): 632-638. [5] Chinese Society of Clinical Oncology Guidelines Working Committee. Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of primary liver cancer 2020 (中国肿瘤学会(CSCO)原发性肝癌诊疗指南(2020年))[M]中国肿瘤学会(CSCO)原发性肝癌诊疗指南(2020年))[M]. Beijing: People's Medical Publishing House, 2020. [6] XU J, ZHANG Y, JIA R, et al.Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open- label, dose escalation and expansion study[J]. Clin Cancer Res, 2019, 25(2): 515-523. [7] HUANG J, MO H, ZHANG W, et al.Promising efficacy of SHR- 1210, a novel anti programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China[J]. Cancer, 2019, 125(5): 742-749 [8] TOPALIAN SL, HODI FS, BRAHMER JR, et al.Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26): 2443-2454. [9] BRAHMER JR, TYKODI SS, CHOW LQ, et al.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J]. N Engl J Med, 2012, 366(26): 2455-2465. [10] NIU ZC, WANG L, WANG ZY.Immune checkpoint inhibitor-related toxicity management expert consensus[J]. Journal of Hebei Medical Univesity(河北医科大学学报), 2021, 42(3): 249-255. [11] PRESOTTO EM, RASTRELLI G, DESIDERI I, et al.Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study[J]. J Endocrinol Invest, 2020, 43(3) : 337-345. [12] POLLACK R, ASHASH A, CAHN A, et al. Immune checkpoint inhibitor-induced thyroid dysfunction is associated with higher body mass index[J]. J Clin Endocrinol Metab, 2020, 105 (10): dgaa458. [13] POLLACK RM, KAGAN M, LOTEM M, et al.Baseline TSH level is associated with risk of anti-PD-1-induced thyroid dysfuction[J]. Endocr Pract, 2019, 25(8): 824-829. [14] SONG Y, WU J, CHEN X, et al.Asingle-arm, multicenter, phaseII study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma[J]. Clin Cancer Res, 2019, 25(24): 7363-7369. [15] QIN SK, REN ZG, MENG ZQ, et al.Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group,randomised, phase 2 trial[J]. Lancet Oncol, 2020, 21(4) : 571-580. [16] HUANG J, XU B, MO H, et al.Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma[J]. Clin Cancer Res, 2018, 24(6): 1296-1304. [17] LICKLITER JD, GAN HK, VOSKOBOYNIK M, et al.A first-in-human dose finding study of camrelizumab in patients with advanced or metastatic cancer in Australia[J]. Drug Des Devel Ther, 2020, 14: 1177-1189. [18] FANG W, YANG Y, MA Y, et al.Camrelizumab(SHR-1210) alone or in combination with gemcitabine plus cisplatin for naso-pharyngeal carcinoma: results from two single-arm, phase 1 trials[J]. Lancet Oncol, 2018, 19(10): 1338-1350. [19] WANG F, QIN SK, SUN XC, et al.Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial[J]. J Hematol Oncol, 2020, 13: 47. [20] EIGENTLER TK, HASSEL JC, BERKING C, et al.Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy[J]. Cancer Treat Rev, 2016, 45: 7-18. |